ArticleExpert review of molecular diagnostics2014
Review of use of a new rapid real-time PCR, the Cepheid GeneXpert® (Xpert) CT/NG assay, for Chlamydia trachomatis and Neisseria gonorrhoeae: results for patients while in a clinical setting.
Article in Expert review of molecular diagnostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03098394 (Use of a Rapid Turnaround Test for Gonorrhea & Chlamydia to Improve Treatment of Women Presenting With Possible Sexually Transmitted Infections), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of a Rapid Turnaround Test for Gonorrhea & Chlamydia to Improve Treatment of Women Presenting With Possible Sexually Transmitted Infections
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Pooled it
- Evaluation of the Diagnostic Efficacy of Xpert CT/NG forBioMed research international · 2020Pooled it
- Meta-analysis of the Cepheid XpertSexual health · 2019Pooled it
- Uptake of and factors associated with testing for sexually transmitted infections in community-based settings among youth in Zimbabwe: a mixed-methods study.The Lancet. Child & adolescent health · 2021Trial
- Rapid and simple detection of Chlamydia trachomatis and Neisseria gonorrhoeae using the EasyNAT CT/NG assay based on cross-priming amplification.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Prevalence and Determinants of Common Sexually Transmitted Infections Among Women Presenting with Vaginal Discharge at a Tertiary Care Hospital in Eritrea.International journal of women's health · 2025Article
- Article
- Clinic-based evaluation of the dual Xpert CT/NG assay on the GeneXpert System for screening for extragenital chlamydial and gonococcal infections amongst men who have sex with men.BMC infectious diseases · 2024Article
- Acceptability, feasibility and cost of point of care testing for sexually transmitted infections among South African adolescents where syndromic management is standard of care.BMC health services research · 2023Observational
- Assessment ofLe infezioni in medicina · 2023Article
- Review
- Article
- Community engagement on-site rapid test for chlamydia and gonorrhea among men who have sex with men: a pioneering study in Guangzhou, China.BMC public health · 2022Article
- A portable magnetofluidic platform for detecting sexually transmitted infections and antimicrobial susceptibility.Science translational medicine · 2021Article
- Potential for Point-of-Care Tests to Reduce Chlamydia-associated Burden in the United States: A Mathematical Modeling Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- The Laboratory Diagnosis ofPathogens (Basel, Switzerland) · 2020Review
- Impact of specimen storage temperature and time on the implementation of GeneXpert® testing for sexually transmitted infections in resource-constraint settings.Journal of microbiological methods · 2019Article
- A diagnostic evaluation of a molecular assay used for testing and treating anorectal chlamydia and gonorrhoea infections at the point-of-care in Papua New Guinea.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2019Article
- Comparison between DiaPlexQ™ STI6 and GeneFinder™ STD I/STD II multiplex Real-time PCR Kits in the detection of six sexually transmitted disease pathogens.Journal of clinical laboratory analysis · 2019Article
- Diagnostic tools for tackling febrile illness and enhancing patient management.Microelectronic engineering · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Rapid diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae are desirable so that patients can be treated while they are still in the clinic or doctor's office. The Cepheid GeneXpert(®) (Xpert) CT/NG assay was US FDA-cleared in December 2012. The assay is a rapid real-time PCR nucleic acid amplified test. The cartridge-based assay detects DNA of Chlamydia trachomatis and Neisseria gonorrhoeae. It is FDA-cleared for use in female endocervical swabs, patient-collected vaginal swabs and for female and male urine specimens from symptomatic and asymptomatic patients. It has demonstrated near-perfect sensitivity and specificity in urogenital specimens. The Xpert is a modular platform for testing samples directly from patients, which requires no hands-on manipulation from specimen loading until results are available. Results are provided in approximately 90 minutes. It has been graded by the FDA as moderately complex for Clinical Laboratory Improvement Amendments. Several publications have reported its promising use in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.